YD Bio (YDES) Operating Leases (2024)
YD Bio's (YDES) quarterly Operating Leases came in at $5.7 billion in Q4 2024.
YD Bio (YDES) Operating Leases (2024) Analysis & Trends
YD Bio (YDES) has 1 years of Operating Leases data on file, last reported at $5.7 billion in Q4 2024.
- On a quarterly basis, Operating Leases changed N/A year-over-year to $5.7 billion in Q4 2024; TTM through Dec 2024 was $5.7 billion, a N/A change from a year earlier, with the FY2024 full-year figure at $5.7 billion, changed N/A from the prior year.
- Operating Leases for Q4 2024 stood at $5.7 billion.
- Over the last five years, Operating Leases for YDES reached as high as $5.7 billion in Q4 2024 and fell as low as $5.7 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.68 Bn |